Researchers at Dana-Farber Cancer Institute are presenting a promising advance in the treatment of chronic lymphocytic ...
Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...
Susan L. Slager, PhD, discusses the background of her research on inherited germline genetics for risk of chronic lymphocytic ...
Current treatments for patients with relapsed or refractory chronic lymphocytic leukemia have shown better outcomes than ...
Meaningful change thresholds for the EORTC Quality of Life Questionnaire in chronic lymphocytic leukemia (CLL) or small ...
This multiyear follow-up of more than 3300 patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who ...
Grandad William Bennett, 69, was diagnosed with chronic lymphocytic leukaemia (CLL) 12 years ago, a type of blood cancer ...
Venclexta already has a fairly broad label in the relapsed/refractory CLL population ... in patients receiving it for multiple myeloma in a trial’s control arm – causing AbbVie and Roche ...
For patients with relapsed or refractory CLL, an expert explained that it’s important to understand the order of how ...
Researchers found no significant differences in the risk of overall adverse events (AEs), but there were significant differences in grade 3 or higher AEs, serious AEs, treatment discontinuations due ...
EMA grants PRIME designation to Nurix Therapeutics’ NX-5948 to treat relapsed or refractory chronic lymphocytic leukaemia: San Francisco Friday, November 22, 2024, 16:00 Hrs [IS ...